This site is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Lonza Partners With Lipogen for PS-Based Formulas

BASEL, Switzerland—Lonza announced a global commercial partnership with Lipogen for the exclusive rights to sell phosphatidylserine (PS) and PS-based formulations in dietary supplements, medical foods and food and beverages under the Lonza name. Lonza intends to roll out launch activities in the United States in the fourth quarter of 2011, and expand to other global regions thereafter.

“Adding PS to our portfolio of branded ingredients directly represents our commitment to provide a diverse line of nutrition products and an array of formulation-friendly technical qualities," said Michael DeGennaro, global VP marketing and sales nutrition at Lonza. “PS represents our focus of bringing solutions that meet the needs for cognitive support to our customers."

David Rutenburg, president of Lipogen Ltd., added: “Our current primary goal is to bring high-quality and efficacious brain-support ingredients to the market. Lonza’s heritage and commitment to those same goals are well recognized in the nutrition industry. Collaborating our efforts with Lonza will further develop the high potential for PS and the modern PS Plus by meeting the needs of improving cognitive well being worldwide."

PS, which may reduce the risk of dementia and cognitive dysfunction in the elderly as well as reduce stress and mental fatigue joins Lonza’s portfolio of nutritional ingredients backed by scientific evidence.  With age the amount of PS naturally diminishes in our brain creating a need for supplementation. PS is the only cognitive health ingredient in the United States that received a qualified health claim from FDA. Lipogen PS  also obtained FDA-affirmed GRAS (generally recognized as safe) status.

comments powered by Disqus